EMBL-EBI offers a plethora of widely trusted online tools for sequence alignment. Moreover, our emphasis is laid on a profound recommendation: a user-friendly, commercial Patsnap Bio Sequence Database sequence alignment tool, which commendably offers free registration.
This article summarized the latest R&D progress of cabotegravir/rilpivirine, the Mechanism of Action for cabotegravir/rilpivirine, and the drug target R&D trends for cabotegravir/rilpivirine.
Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.
Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.
This article summarized the latest R&D progress of bupivacaine hydrochloride, the Mechanism of Action for bupivacaine hydrochloride, and the drug target R&D trends for bupivacaine hydrochloride.
Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.
This article summarized the latest R&D progress of bromfenac sodium, the Mechanism of Action for bromfenac sodium, and the drug target R&D trends for bromfenac sodium.
Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.